Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Inhaled nitric oxide therapy in adults


Published on

Published in: Health & Medicine
  • Be the first to comment

Inhaled nitric oxide therapy in adults

  1. 1. Inhaled Nitric Oxide Therapy in Adults Authors: Mark J.D. Griffiths, M.R.C.P., Ph.D., and Timothy W. Evans, M.D., Ph.D From: NEJM 353;25 December 22, 2005 Presenter: R5 謝廣宇 Supervisor: Dr. VS 陳奇祥本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時 , 須獲得原期刊之同意授權
  2. 2. Introduction NO and endothelium-derived relaxing factor →modulating vascular tone through stimulated formation of cyclic guanosine 3,5- monophosphate NO is formed from semiessential amino acid L- arginine by one of three (neural, inducible, and endothelial) isoforms of nitric oxide synthase In 1991, inhaled NO →selective pulmonary vasodilator in patients with pulmonary hypertension, as well as in animals with pulmonary hypertension induced by drugs or hypoxia.
  3. 3.  NO in ARDS →↓ pulmonary vascular resistance without affecting BP and ↑ oxygenation by redistributing pulmonary blood flow toward ventilated lung units….BUT →licensed indications are restricted to pediatric practice This review → biologic actions of inhaled NO , clinical indications in adults, possible future developments
  4. 4. chemical reactions of inhaled nitricoxide Atmospheric concentrations →between 10 and 500 parts per billion but may reach 1.5 parts per million (ppm) in heavy traffic12 and 1000 ppm in tobacco smoke NO is potentially cytotoxic, and covalent nitration of tyrosine in proteins by reactive nitrogen species has been used as a marker of oxidative stress
  5. 5.  NO is rapidly inactivated by hemoglobin in blood by haptoglobin–hemoglobin complexes in plasma → forms nitrosylhemoglobin ; in lung →methemoglobin and nitrate on reaction with oxyhemoglobin →reduced to ferrous hemoglobin by NADH–cytochrome b5 reductase in erythrocytes 70 % inhaled NO is excreted as nitrate in the urine within 48 hours
  6. 6.  >100 proteins, including hemoglobin and albumin, contain reduced sulfur (thiol) → react reversibly with NO to form S- nitrosothiols → vasodilators that inhibit platelet aggregation, also “store” nitric oxide within the circulation
  7. 7. physiologic effects of inhaled nitric oxideon the cardiovascular system
  8. 8.  Inhaled NO relaxes pulmonary vessels → ↓pulmonary vascular resistance, pulmonary arterial pressure, and right ventricular afterload rapid hemoglobin-mediated inactivation of NO biventricular cardiac failure →inhaled NO → ↑ pulmonary blood flow →↑pulmonary edema
  9. 9.  positive effect of inhaled NO on gas exchange depends on the extent to which pulmonary vasoconstriction and ventilation–perfusion mismatching are contributing to impaired oxygenation → study of mountaineers vascular selectivity →disproportionate arterial, as opposed to venous →dilatation →↑pulmonary-capillary pressure→ may ↑risk of pulmonary edema ( but NO 40 ppm induced venodilatation→ ↓pulmonary edema)
  10. 10.  NO decreasing inflammation and helping maintain the integrity of the alveolar- capillary membrane in animal studies inhaled NO has no effect on systemic circulation… BUT experimental studies have demonstrated ↓systemic vascular resistance, restoration of mesenteric perfusion after inhibition of NO synthase
  11. 11.  rapid withdrawal may induce rebound pulmonary hypertension and hypoxemia →↓endothelial NO synthase activity →↑ plasma concentrations of endothelin-1.. BUT large clinical studies didn’t support it
  12. 12. direct cytotoxicity and effectson inflammation protective effects →specific effects on neutrophil function→ attenuation of the respiratory burst and neutrophil-derived oxidative stress, ↓neutrophils in the pulmonary vasculature and air space in animal models of ALI, NO derived from neutrophils acts as an autocrine modulating factor in infiltration of neutrophils into the lungs during sepsis
  13. 13.  endogenously produced NO contributes to control and killing of multiple pathogens and malignant cells. NO–derived reactive nitrogen species contribute to epithelial damage after a variety of insults →unpredictable and probably depend on the relative local concentrations →↑oxidative products of NO in airway-lining fluid of patients with ARDS and MAYBE may be further increased by inhalation of NO
  14. 14.  In rodents, inhalation of nitric oxide (20 ppm) did not increase protein nitration unless hyperoxia was superimposed Endogenous NO inhibits adhesion of platelets to endothelial cells and subsequent aggregation → inhalation NO not certain
  15. 15.  Reactive nitrogen species →↓ functions of surfactant →animals receiving inhaled high-dose nitric oxide (80 to 100 ppm) had ↓ capacity to lower surface tension…. But inhaled NO ↑surfactant proteins in four- week-old lambs, NOT certain in human Inhaled NO has a dose-dependent bronchodilator effect →nitric oxide– derived S-nitrosothiols
  16. 16. administration of inhaled nitric oxideto adults Limiting mixing of NO with high concentrations of inspired oxygen ,and mixture of NO and nitrogen into inspiratory limb of ventilator tubing as near to patient as possible , synchronizing injection of the mixture with inspiration →↓risk of adverse effects resulting from formation of nitrogen dioxide a massive overdose of inhaled NO (500 to 1000 ppm) is rapidly fatal →< 40 ppm for up to 6 months…. Safe in animals
  17. 17.  < 40 ppm of inhaled NO administered clinically should not cause methemoglobinemia →check methemoglobin within 6 hours after initiation of NO therapy and after each increase in the dose( UK guideline) environmental concentrations of NO and NO2 should not exceed a time-weighted average of 25 ppm and 2 ppm, respectively, over an 8 hours period----The Control of Substances Hazardous to Health Regulations -----( unlikely in a well-ventilated room)
  18. 18. Dose–Response Relationship higher doses were required to treat pulmonary hypertension than to improve oxygenation a minority of patients have no response when a response is defined as a 20 percent increase in oxygenation →No radiologic or physiological variables predict a response
  19. 19.  30 % ↓pulmonary vascular resistance during inhalation of NO (10 ppm for 10 minutes) has been used to identify an association with vascular responsiveness to agents that can be helpful in the long term (like calcium-channel blockers)
  20. 20.  Dose–response relationships ( NO, 0 to 100 ppm) were constructed in the two groups on days 0, 2, and 4 → first, the dose– response curves for changes in oxygenation and mean pulmonary pressure were shifted to left only in patients who inhaled nitric oxide (10 ppm) continuously. Second, “supramaximal” doses of NO were associated with worsening oxygenation------- Gerlach H, et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med 2003;167:1008-15.
  21. 21. clinical indications for administeringinhaled nitric oxide to adults failed to determine the therapeutic role of inhaled nitric oxide in patients with acute respiratory failure no decrease in duration of mechanical ventilation or the mortality rate----similar at 30 days (European multicenter study enroll 600 subjects enrolled 268 patients with early ALI) ↑oxygenation (specifically in the partial pressure of arterial oxygen) lasted only for the first day of therapy
  22. 22.  why are the effects of inhaled NO so short- lived?------↑sensitivity to NO during its inhalation may diminish its beneficial effects and increase toxicity, constant inhalation may lead to equilibration of vasodilator effect between ventilated and nonventilated areas any continued benefit may depend on use of other therapeutic approaches such as maintaining alveolar recruitment
  23. 23.  if clinical benefits are real, why do they not translate into improved outcome?-----ARDS is a heterogeneous condition with multiple causes requiring different interventions that independently affect outcome, very large numbers of patients would be required for a study to demonstrate benefit------many large studies evaluating modes of ventilation and prone positioning in patients with ARDS have shown no correlation between improved oxygenation and the outcome----majority die from multiorgan failure
  24. 24. Targeting Pulmonary Vascular Resistance ↓expression of endothelial NO synthase in pulmonary arteries of patients with chronic primary and secondary pulmonary hypertension→ possible therapeutic role for nitric oxide →Inhaled NO improves hemodynamic variables and exercise tolerance in patients with chronic pulmonary hypertension of various causes
  25. 25.  inhaled NO alleviates pulmonary HTN in severe COPD but exacerbates hypoxemia at rest----- BUT pulsed therapy (O2 with inhaled NO as a bolus after the start of inspiration) markedly ↓ pulmonary arterial pressure and ↑ cardiac output without impairing oxygenation (Vonbank K,et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003;58:289-93) During exercise, inhaled NO alleviates pulmonary HTN without inducing hypoxemia
  26. 26. Lung Transplantation ischemia and reperfusion and oxidative stress is an important cause of morbidity and mortality after lung transplantation--- also ↓Endogenous NO activity----- randomized, placebo-controlled trial of 84 transplant recipients, starting 10 minutes after reperfusion and continuing for a minimum of 6 hours, demonstrated no benefit in terms of oxygenation, the time to extubation, or the 30-day mortality rate.
  27. 27. Sickle Cell Disease results in widespread chronic inflammation and recurrent ischemia–reperfusion injury in organs such as the lungs and is caused by microvascular occlusion by stiff erythrocytes containing polymerized deoxyhemoglobin S-----high-dose inhaled NO (80 ppm for 1.5 hours) →↓scavenging potential of hemoglobin within the circulation (because of the weak interaction of nitric oxide with methemoglobin)
  28. 28. alternatives and adjuncts to inhalednitric oxide aerosolized sodium nitrite Epoprostenol, the most extensively studied alternative to inhaled NO, also an endothelium- derived vasodilator with antithrombotic effects--- longer half-life (three to six minutes), causing recirculation ---- greater pulmonary and systemic hypotensive effect, but causes less improvement in oxygenation Inhaled NO and nebulized prostacyclin have been observed to have additive effects
  29. 29.  Nebulized epoprostenol (10 to 50 ng per kilogram per minute) , Iloprost, a long- acting prostacyclin analogue (half-life, 20 to 30 minutes) , Inhaled prostaglandin E1 (6 to 15 ng per kilogram of body weight per minute)
  30. 30. Adjunctive Therapies That Increase the Effectivenessof Inhaled Nitric Oxide sildenafil, an inhibitor of phosphodiesterase type 5, is a selective pulmonary vasodilator, partially because phosphodiesterase type 5 is highly expressed in the lung ---- augmented pulmonary vasodilatation induced by NO inhalation But zaprinast, predictably worsened oxygenation through the attenuation of hypoxic pulmonary vasoconstriction in an ovine model of acute lung injury---most useful when pulmonary HTN rather than respiratory failure
  31. 31.  Almitrine, an agonist at peripheral arterial chemoreceptors, is a selective pulmonary vasoconstrictor that specifically enhances hypoxic pulmonary vasoconstriction PEEP , prone positioning, or ventilatory maneuvers designed to inflate collapsed lung Partial liquid ventilation with perfluorocarbons facilitates delivery of dissolved gases to alveoli by enhancing recruitment of injured lung units
  32. 32. conclusionsand future directions Large clinical trials have indicated that physiologic benefits are short-lived in adults with acute lung injury or ARDS, and no associated improvement in mortality rates has been demonstrated------- statistically underpowered to show a decrease in mortality rates and have not considered recent insights into effect of continuous inhalation on dose– response relationship of this agent
  33. 33.  On basis of evidence, inhaled NO is not an effective therapeutic intervention in patients with acute lung injury or ARDS, and its routine use to achieve this end is inappropriate-----may be useful as a short- term adjunct therapy